Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

What’s becoming clear is that obesity isn’t one disease — it’s many, said Jack Yanovski, a senior obesity researcher at the ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has emerged as a prominent player in the rare disease treatment landscape, with its recent FDA approval and launch of VYKAT XR for Prader-Willi Syndrome (PWS) ...

VYKAT XR’s strong efficacy data, particularly its demonstrated ability to address multiple aspects of PWS beyond hyperphagia, positions it as a potential standard of care.